Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Defining Reversal of Alopecia Areata (AA) Phenotype With Dupilumab in Patients With and Without Associated Atopic Dermatitis (AD)

NCT03359356 is registered in ClinicalTrials.gov with Icahn School of Medicine at Mount Sinai as lead sponsor.

NCT NCT03359356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03359356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Defining Reversal of Alopecia Areata (AA) Phenotype With Dupilumab in Patients With and Without Associated Atopic Dermatitis (AD)
Lead sponsor
Icahn School of Medicine at Mount Sinai
Phase
Phase 2
Overall status
Completed
Start date
January 9, 2018
Completion date
December 17, 2020
Enrollment
60 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

alopecia areata